Abstract: Disclosed is a pharmaceutical composition for treating chronic obstructive pulmonary disease, comprising an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method for treating chronic obstructive pulmonary disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent.

Abstract: Disclosed is a pharmaceutical composition for treating ischemic stroke, comprising an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method for treating ischemic stroke in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of human mesenchymal stem cells, human serum albumin, and a pharmaceutically acceptable carrier or diluent. In addition, a method for promoting secretion of hepatocyte growth factor by human mesenchymal stem cells is disclosed.

Abstract: A method of distinguishing mesenchymal stem cells (MSCs) from fibroblasts is provided. Also provided is a method of increasing a purity of mesenchymal stem cells (MSCs) population in a cell culture. The above-mentioned methods each comprise a step of sorting or isolating the cells by a marker of CD146 from a cell culture derived from a placenta-related tissue. Further provided is a method of assessing purity of mesenchymal stem cells (MSCs) in a cell culture derived from a placenta-related tissue, comprising determining the percentage of cells expressing CD146 in the culture.

Abstract: A method of distinguishing mesenchymal stem cells (MSCs) in a primary culture of cells derived from a placenta-related tissue is provided. Also provided is a method of increasing the purity of MSC population in a primary culture of cells derived from a placenta-related tissue. Further provided is a method of isolating a MSC population which is more responsive in an inflammatory environment. Said methods each comprise a step of sorting the cells by a marker of EphA2.

Abstract: A method of distinguishing mesenchymal stem cells (MSCs) in a primary culture of cells derived from a placenta-related tissue is provided. Also provided is a method of increasing the purity of MSC population in a primary culture of cells derived from a placenta-related tissue. Further provided is a method of isolating a MSC population which is more responsive in an inflammatory environment. Said methods each comprise a step of sorting the cells by a marker of EphA2.